Pricing Log in Create free account

Denali Therapeutics Inc. (DNLI) vs Arcus Biosciences, Inc. (RCUS)

Denali Therapeutics Inc. and Arcus Biosciences, Inc. are both Biotechnology companies. Denali Therapeutics Inc. and Arcus Biosciences, Inc. are of similar size ($2.9B and $2.9B). Denali Therapeutics Inc. grew revenue faster over the last twelve months: 194.7% against −55.3%. Denali Therapeutics Inc. has the higher net margin (−171.1% vs −393.2%) and the lower return on invested capital (−260.5% vs 0.00%). Across the 18 metrics below, Denali Therapeutics Inc. leads on 14 and Arcus Biosciences, Inc. on 4.

Valuation

Metric DNLI RCUS Biotechnology median
P/E n/m n/m 8.50
P/S 11.00 23.84 9.71
P/B 3.94 6.01 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 8.64 18.70 9.21
Earnings yield (16.17%) (17.63%) (33.15%)
Free cash flow yield (13.30%) (17.07%) (25.50%)

Profitability

Metric DNLI RCUS Biotechnology median
Gross margin 99.97% 100.00% 65.16%
Operating margin (181.51%) (415.38%) 0.00%
Net margin (171.06%) (393.16%) 0.00%
Free cash flow margin (146.31%) (405.13%) 0.00%
Return on equity (54.93%) (90.82%) (56.36%)
Return on assets (44.01%) (46.02%) (48.04%)
Return on invested capital (260.54%) 0.00% 0.00%

Growth

Metric DNLI RCUS Biotechnology median
Revenue growth (TTM) 194.68% (55.34%) 6.02%
EPS growth (last fiscal year) (15.56%) (4.78%) 30.26%
Revenue growth, 5-year CAGR 20.67% 25.93% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DNLI RCUS Biotechnology median
Debt to equity 0.01 0.22 0.00
Current ratio 8.37 3.82 4.72
Net debt to EBITDA 1.56 2.27 0.96

Dividend

Metric DNLI RCUS Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric DNLI RCUS Biotechnology median
Market cap 2.93b 2.91b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack